Published in final edited form as:

Bioorg Med Chem Lett. 2010 March 15; 20(6): 2029–2032. doi:10.1016/j.bmcl.2010.01.068.

Synthesis and Chain-Dependent Antifungal Activity of Long-Chain 2*H*-Azirine-Carboxylate Esters Related to Dysidazirine

Colin K. Skepper^a, Doralyn S. Dalisay^a, and Tadeusz F. Molinski^{a,b,*}

^aDepartment of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093

^bSkaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093

Abstract

Analogues of the antifungal marine natural product (*E*)-dysidazirine were prepared and evaluated in broth ro-dilution assays against a panel of fungal pathogens. A simple structure-activity relationship was developed which provides insight into the mechanism of action of long-chain 2*H*-azirine carboxylates.

Keywords

antifungal; oxazole; azole; marine natural product

2*H*-Azirines are highly strained, weakly aromatic heterocycles rarely found in Nature. In fact, only nine natural products containing the 2*H*-azirine ring have been described to date. Azirinomycin¹ (**1**) was isolated from *Streptomyces aureus* while the other compounds constitute a small family of long-chain 2*H*-azirine carboxylates. The first of this family, (*E*)-dysidazirine (**2**), was isolated in 1988 from the marine sponge *Dysidea fragilis*, collected in Fiji, and shown to exhibit potent antifungal activity against *Candida albicans* and *Saccharomyces cerevisiae* (4 µg/disk, disk diffusion assay).² Faulkner and coworkers later characterized (*Z*)-dysidazirine (**3**) and two ω-dibromovinylidene azirine-2-carboxylate methyl esters, **4** and **5** (*E*- and *Z*-antazirines) from *D. fragilis* and reported them as inactive “against a standard panel of roorganisms”.³ Motualevic acid F, the parent carboxylic acid of *ent*-**4**, was reported by Bewley and coworkers along with related amides from *Siliquariaspongia* sp. with antibacterial activity against *Staphylococcus aureus* and MRSA.⁴ In our search⁵ for antifungal compounds from marine organisms with efficacy against Fluconazole-resistant strains of *Candida* and other pathogenic yeast,⁶ we found three new antazirines (**6–8**) along with **4** and **5** from a sample of *Dysidea fragilis* collected in Pohnpei, Micronesia that showed cytotoxicity in a crude screen.⁷ Compounds **4–8** were moderately cytotoxic (HCT-116 cells), but to our surprise they were completely inactive against a panel of fungal pathogens including *Candida albicans* (ATCC, UCD-FR1 and 96–489), less susceptible, non-*albicans* species such as *C. glabrata* and *C. krusei*, and two strains of *Cryptococcus neoformans*, var. *grubii* and *gatti*.

© 2009 Elsevier Ltd. All rights reserved

*Corresponding author: Tel: +1 858 534-7115; Fax: +1 858 822-0386; tmolinski@ucsd.edu.

[†]Present address: Department of Chemistry, University of British Columbia, Vancouver, BC, Canada V6T 1Z1

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

In order to elucidate the relationship between structure and antifungal activity of long-chain 2*H*-azirine carboxylates we carried out the first synthesis of (*Z*)-dysidazirine⁸ and a short series of structural analogues ((-)-**9**→**13**, Figure 2), along with (*E*)-dysidazirine. We report here the structure-activity relationships for (-)-**2**, (-)-**3**, (±)-**3** and (-)-**9**→**13** that reveal structural determinants for antifungal activity, including terminal branching [(-)-**9**], chain length [(-)-**10** and (-)-**11**], C4–C5 unsaturation [(-)-**12**, (-)-**13**] and C2 configuration [(±)-**3**].

The synthesis of (-)-(*Z*)-dysidazirine and analogues (-)-**9** and (-)-**12** has been described previously.⁸ Photocheal isomerization (500W sunlamp, Pyrex) of synthetic (-)-**3** (59% ee) provided (-)-**2** (Scheme 1) in low yield but without epimerization at C2. Natural dysidazirine and congeneric compounds have all been isolated as non-race mixtures of enantiomers. Neat, natural dysidazirine spontaneously epimerizes slowly in the dark (*t*_{1/2} ~12y, -20 °C),⁷ and the lack of racemization of **2** and **3** in the presence of light excludes a photocheal mechanism.

The shorter chain analogues (-)-**10** and (-)-**11** were prepared in an analogous fashion to (-)-**3** (Scheme 2). Addition of the lithio-acetylide derived from alkyne **14** to methyl malonyl chloride gave β-ketoester **15** in reasonable yield (55%). Treatment of **15** with NH₂OH•HCl/pyridine led to the corresponding oxime which was converted to oxime tosylate **16** without purification. Cyclization in the presence of quinidine under Zwanenburg's conditions⁹ provided 2*H*-azirine **17** in excellent yield. Partial hydrogenation with Lindlar's catalyst provided the truncated dysidazirine analogue (-)-**11**. The same sequence applied to alkyne **18** gave analogue (-)-**10**.

Synthesis of (-)-**13**, the 4,5-dihydro analogue of **3**, began with generation of the enolate of dioxolane **19** (LDA, HMPA, -40 °C) followed by alkylation with 1-bromotetradecane (**20**) to provide **21** in low yield (18%) along with an equivalent amount of the product from α-alkylation (Scheme 3). Thermolysis of **21** (rowave) gave the incipient ketene that was captured with methanol to afford *O*-methyl β-ketoester **22** that was subsequently converted to oxime tosylate **23** in two steps as before. Treatment of **23** with quinidine led directly to (-)-**13** in 91% yield.

The antifungal s of the synthetic and natural azirines are compared in Figure 4.¹⁰ Each yeast strain was susceptible to (-)-**3** and some synthetic analogues with the notable exception of Fluconazole-resistant *C. krusei*. The other Fluconazole-resistant strains (*C. glabrata*, *C. albicans* UCSD-FR1 and 96–489) were all susceptible. Strains of *Cryptococcus neoformans* (var. *grubii* and var. *gatti*) were the most susceptible overall.

Both (-)-**2** and (-)-**3** were consistently amongst the most active compounds against all strains, with *50* values in the range of 2–8 μg/mL. For *Candida* spp., (-)-**3** was notably more active than (-)-**2** (Figure 4a). Shorter chain analogues (-)-**10** and (-)-**11** were comparable in activity to (-)-**3**, although Fluconazole-resistant *C. albicans* UCD-FR1 was susceptible to (-)-**10**, but not to (-)-**11**.

Alkynyl analogue (-)-**12** retains most of the activity of the natural products (-)-**2** and (-)-**3**, however the 4,5-dihydro analogue (-)-**13** lost activity across the entire panel of fungal cells. The C2 configuration appears to be less important. Race *Z*-dysidazirine [(±)-**3**] shows good activity against all strains, comparable to or slightly better than the optically enriched homologue (-)-**3**.

As previously observed,⁸ the *tert*-butyl terminus analogue (-)-**9** is essentially inactive. Clearly terminal substitution or branching abrogates antifungal activity, consistent with the lack of activity for ω-halo-alkenyl antiazirines (**4**–**8**).^{3,7}

The foregoing results suggest specific structural attributes determine antifungal activity rather than non-specific toxicity. Our original hypothesis regarding a putative sub-cellular target of

dysidazirine, based on data obtained from (–)-**3** and (–)-**9**, is supported by the wider range of analogues presented here.⁸ We favor a model for activity of long-chain azirines involving interaction with a putative protein target through a 2-point binding motif and propose the following. We envision the lipid chain occupies a tightly constrained hydrophobic pocket that is intolerant of bulky ω -substitution, which helps to explain the loss of activity seen for **4–8** and (–)-**9** despite log*P*s and molecular size that are comparable to (–)-**3**. The polar, electrophilic azirine terminus – a potent hael acceptor capable of covalent modification of nucleophilic sites (e.g. cysteine, lysine) – binds at a distal site, possibly interacting with one or more nucleophilic amino acid residues. The absolute requirement of C4–C5 unsaturation for high antifungal activity supports the latter hypothesis. (Z)-Dysidazirine [(–)-**3**], which is expected to be a superior hael acceptor to (–)-**2**, shows enhanced antifungal activity against *Candida albicans* strains.

The structure of dysidazirine bears a resemblance to phytosphingosine (**24**) and sphingosine (**25**) (Figure 5) – both **24** and **25** share the same carbon chain length (C₁₈) as dysidazirine. The long-chain base **24** occurs in plant and fungal cells and acts in multiple capacities, both as a cellular structural component and a signaling molecule.¹¹ Sphingosine (**25**) is the primary long-chain base of mammalian cells; it also plays roles in cell structure and signaling, and exhibits modest antifungal activity (30 μ g/mL, *C. glabrata*).¹²

Several long-chain vicinal aminoalcohol marine natural products (Figure 5) also exhibit antifungal activity,⁵ including crucigasterins 275 (**26**) and 277 (**27**),¹³ (R)-1-aminotridecen-2-ol¹⁴ (**28–30**) and oceanapiside (**31**),¹⁵ an unusual 'two-headed' sphingoid base.¹⁶

Natural products dysidazirine (–)-**3**, other long-chain azirines and **31** resemble sphingosine or its immediate precursor sphinganine (4,5-dihydrosphingosine) and may act as antimetabolites that competitively inhibit sphingolipid metabolism.

The biosynthesis of **24** and **25** in yeast follows the canonical sphingolipid pathway that begins with pyridoxal phosphate-dependent condensation of palmitoyl CoA thioester with serine. Long-chain azirines may compete for natural substrate in the condensation reaction or downstream reactions that tailor **24** and **25**. It is notable that the antifungal properties of **3** and other sphingoid base analogues are not solely determined by the presence of a long hydrophobic tail since simple lipids are inactive and other antifungal long-chain fatty acid conjugates appear to act by distinctly different mechanisms.¹⁷

In summary, we have completed the synthesis of a series of dysidazirine analogues and evaluated each for antifungal activity against a panel of clinically-relevant yeasts. Several generalizations can be made: 1) C4–C5 unsaturation is required for high activity. 2) Activity is not strongly dependent on minor changes in chain length or the configuration at C2. 3) Terminal branching of the lipid chain abolishes activity. Further investigations are underway in our laboratories to identify high-affinity binding targets of (–)-**3**.

Acknowledgments

The NSF CRIF program (CHE0741968) is acknowledged for acquisition of the 500 MHz NMR spectrometers. We are grateful to the NIH for generous funding of this research (AI 039987).

References and Notes

1. Miller TW, Tristram EW, Wolf FJ. J. Antibiot 1971;24:48–50. [PubMed: 5541332]
2. Molinski TF, Ireland CM. J. Org. Chem 1988;53:2103–2105.
3. Salomon CE, Williams DH, Faulkner DJ. J. Nat. Prod 1995;58:1463–1466. [PubMed: 7494151]
4. Keffer JL, Plaza A, Bewley CA. Org. Lett 2009;11:1087–1090.

5. Molinski TF. *Curr. Med. Chem.: Anti-Infect. Agents* 2004;3:197–220.
6. a) White TC, Holleman S, Dy F, Mirels LF, Stevens DA. *Antirob. Agents Chemother* 2002;46:1704–1713. b) Lyons CN, White TC. *Antirob. Agents Chemother* 2000;44:2296–2303. c) White TC, Marr KA, Bowden RA. *Clin. microbiol. Rev* 1998;11:382–402. d) Collin B, Clancy CJ, Nguyen MH. *Drug Resist. Updates* 1999;2:9–14. e) Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, Lortholary O. *J. Antirob. Chemotherapy* 2006;57:384–410.
7. Skepper CK, Molinski TF. *J. Org. Chem* 2008;73:2592–2597. [PubMed: 18321120]
8. a) Skepper CK, Dalisay DS, Molinski TF. *Org. Lett* 2008;10:5269–5271. [PubMed: 18937483] b) Skepper, CK. Ph.D. Thesis. University of California at San Diego; Dec. 2009
9. Verstappen MMH, Ariaans GJA, Zwanenburg B. *J. Am. Chem. Soc* 1996;118:8491–8492.
10. The *in vitro* susceptibilities were determined by the broth micro dilution method according to the guidelines of the NCCLS: National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. a) Sims KJ, Spassieva SD, Voit EO, Obeid LM. *Biochem. Cell Biol* 2004;82:45–61. [PubMed: 15052327] b) Dickson, RC.; Lester, RL. Chapter 9. In: Hirabayashi, Y.; Igarashi, Y.; Merrill, AH., Jr., editors. *Sphingolipid Biology*. Springer; New York; 2006. p. 141 c) Funato K, Vallée B, Riezman H. *Biochemistry* 2002;41:15105–15114. [PubMed: 12484746]
12. Nicholas GN, Li R, MacMillan JB, Molinski TF. *Bioorg. Med. Chem. Lett* 2002;12:2159–2162. [PubMed: 12127527]
13. Jares-Erijman EA, Bapat CP, Lithgow-Bertelloni A, Rinehart KL, Sakai R. *J. Org. Chem* 1993;58:5732–5737.
14. Searle PA, Molinski TF. *J. Org. Chem* 1993;58:7578–7580.
15. Nicholas GM, Hong TW, Molinski TF, Lerch ML, Cancilla MT, Lebrilla CB. *J. Nat. Prod* 1999;62:1678–1681. [PubMed: 10654417]
16. For other examples, see Makarieva TN, Zakharenko AM, Dmitrenok PS, Guzii AG, Denisenko, Alexandra VA, Savina S, Dalisay DS, Molinski TF, Stonik VA. *Lipids* 2009;44:1155–1162. [PubMed: 19882184] . Makarieva TN, Zakharenko AM, Dmitrenok PS, Guzii AG, Denisenko, Alexandra VA, Savina S, Dalisay DS, Molinski TF, Stonik VA. *Lipids* 2009;44:1155–1162. [PubMed: 19882184] , and references cited within.
17. Mulder RJ, Shafer CM, Dalisay DS, Molinski TF. *Bioorg. Med. Chem. Lett* 2009;19:2928–2930. [PubMed: 19419860]
18. Molinski TF. *J. Nat. Prod* 1993;56:1–8. [PubMed: 8450313]

Figure 1.
Naturally occurring 2H-azirines.

Figure 2.
Targeted synthetic dysidazirine analogues.

Figure 4.

Antifungal activity of (-)-2, (-)-3, (±)-3 and (-)-9→13 against: (a) *Candida albicans*, three strains: ATCC 14503, UCD-FR1 and 96-489 (see ref. 18). (b) *Candida glabrata* and *Candida krusei* (c) *Cryptococcus neoformans* var. *grubii* and *gatti*. Compounds with off-scale 50s were inactive up to $64\text{ }\mu\text{g/mL}$.

Figure 5.
Structures of sphingoid bases and antifungal long-chain aminoalcohol marine natural products.

Scheme 1.

Photochemical isomerization of (-)-(Z)-dysidazirine to (-)- (E)-dysidazirine.

Scheme 2.
 Synthesis of truncated analogues **(-)-10** and **(-)-11**.

Scheme 3.
Synthesis of 4,5-dihydrodysidazirine [(-)-13].